Zobrazeno 1 - 10
of 1 699
pro vyhledávání: ''
Autor:
Won Kyung Cho, Chel Hun Choi, Kyoung Won Noh, Byoung-Gie Kim, Bomi Kim, Yoo-Young Lee, Jeong-Won Lee, Won Soon Park, Duk-Soo Bae, Tae-Joong Kim
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Objective: This study aimed to evaluate the effect of waiting time from diagnosis to initiation of definitive concurrent chemoradiation (CCRT) on overall survival in patients with cervical cancer. Methods: Patients with cervical cancer who had defini
Publikováno v:
Cancer Biomarkers. 32:559-567
BACKGROUND: CA125 level normalization at different chemotherapy cycles has been reported to be a prognosticator in advanced epithelial ovarian cancer. OBJECTIVE: In the present study, we investigated whether the time (in days) to CA125 normalization
Autor:
Courtney Nicole Miller-Chism, Harinder S. Juneja, Curtis Lachowiez, Hilary Y. Ma, Martha P. Mims, Wei Qiao, Onyebuchi Ononogbu, Mark M. Udden, Effrosyni Apostolidou
Publikováno v:
Clin Lymphoma Myeloma Leuk
Despite therapeutic advances and improvement in outcomes of patients with acute lymphoblastic leukemia, as reported by specialized centers, healthcare disparities exist. This is a retrospective cohort analysis of the clinical outcomes of 146 patients
Autor:
Boris Kollárik, Michal Mego, Zuzana Sycova-Mila, Jozef Mardiak, Jan Slopovsky, Katarina Rejlekova, Michal Chovanec, Patrik Palacka, Jana Obertova
Publikováno v:
Anticancer Research. 41:5749-5759
BACKGROUND/AIM Systemic immune-inflammation index (SII) predicts survival of patients with various malignancies. This study explored the prognostic value of SII in metastatic urothelial carcinoma (MUC) subjects. PATIENTS AND METHODS We evaluated 181
Autor:
Shogo Teraoka, Atsushi Takenaka, Katsuya Hikita, Masashi Honda, Hideto Iwamoto, Shuichi Morizane, Bunya Kawamoto, Noriya Yamaguchi, Tetsuya Yumioka, Ryutaro Shimizu
Publikováno v:
Anticancer Research. 41:5767-5773
BACKGROUND This study aimed to investigate the response to platinum-based chemotherapy rechallenge in patients with pembrolizumab-refractory urothelial carcinoma. PATIENTS AND METHODS We retrospectively reviewed 14 patients with pembrolizumab-refract
Autor:
Mitsunobu Otsuru, Hiroshi Kurita, Nobuhiro Yamakawa, Masahiro Umeda, Masaya Okura, Tomofumi Naruse, Yoshihide Ota, Tadaaki Kirita, Masashi Sasaki, Souichi Yanamoto, Shin-ichi Yamada, Yukari Shintani, Tatsushi Matsumura
Publikováno v:
Anticancer Research. 41:5785-5791
Background/aim This study was conducted to compare the efficacy and safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma (R/M OSCC).
Publikováno v:
Anticancer Research. 41:5569-5575
Background/aim While controversial, cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) and early postoperative intra-peritoneal chemotherapy (EPIC) remains the mainstay of treatment for low grade appendiceal neoplasm with p
Autor:
Masanobu Enomoto, Akihiko Tsuchida, Tomoya Tago, Katsutoshi Sugimoto, Tetsuo Ishizaki, Yuichi Nagakawa, Kenta Kasahara, Kenji Katsumata, Junichi Mazaki, Ryutaro Udou, Hiroshi Kuwabara, Takao Itoi
Publikováno v:
Anticancer Research. 41:5539-5547
Background/aim We aimed to investigate the prognosis of patients who received radiofrequency ablation (RFA) for liver metastases of unresectable colorectal cancer (CRC). Patients and methods We retrospectively compared 147 patients treated for CRC li
Autor:
Adrian C. L. Kee, Yu Yang Soon, Yvonne Ang, Alvin Wong, Folefac Aminkeng, Sen Hee Tay, Ross A. Soo, Boon Cher Goh, Yiqing Huang
Publikováno v:
International Journal of Cancer. 150:636-644
Immune-related adverse events (IrAEs) of immune checkpoint inhibitors (ICIs) can be serious and unpredictable. We examine the incidence rate and risk factors for IrAEs in an Asian cohort of nonsmall cell lung cancer (NSCLC) patients treated with immu
Publikováno v:
Future Oncology. 17:3925-3940
Aims: This study aimed to retrospectively determine the influence factors and survival effects of chemotherapy in pathological T3N0M0 esophageal cancer (EC) patients based on histological type. Methods: A total of 1136 pathological T3N0M0 EC patients